Implementation of patient‐reported outcome measures in a heart transplant recipient registry: First step toward a patient‐centered approach

Mahmoudi, Redouane; Moitie, Tiphaine; Dorent, Richard; Guillemin, Françis; Couchoud, Cécile

doi:10.1111/ctr.14708

Cited by 7 publications

(3 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, hsTnT levels were independently associated with low DAOH. This is an important finding, as this complements the current knowledge on more patient-centered outcomes in the field of end-stage heart failure and HTX surgery [21,29,30].…”

Section: Discussionsupporting

confidence: 57%

Postoperative high-sensitivity troponin T predicts 1-year mortality and days alive and out of hospital after orthotopic heart transplantation

et al. 2023

View full text Add to dashboard Cite

Background Orthotopic heart transplantation (HTX) is the gold standard to treat end-stage heart failure. Numerous risk stratification tools have been developed in the past years. However, their clinical utility is limited by their poor discriminative ability. High sensitivity troponin T (hsTnT) is the most specific biomarker to detect myocardial cell injury. However, its prognostic relevance after HTX is not fully elucidated. Thus, this study evaluated the predictive value of postoperative hsTnT for 1-year survival and days alive and out of hospital (DAOH) after HTX. Methods This retrospective cohort study included patients who underwent HTX at the University Hospital Duesseldorf, Germany between 2011 and 2021. The main exposure was hsTnT concentration at 48 h after HTX. The primary endpoints were mortality and DAOH within 1 year after surgery. Receiver operating characteristic (ROC) curve analysis, logistic regression model and linear regression with adjustment for risk index for mortality prediction after cardiac transplantation (IMPACT) were performed. Results Out of 231 patients screened, 212 were included into analysis (mean age 55 ± 11 years, 73% male). One-year mortality was 19.7% (40 patients) and median DAOH was 298 days (229–322). ROC analysis revealed strongest discrimination for mortality by hsTnT at 48 h after HTX [AUC = 0.79 95% CI 0.71–0.87]. According to Youden Index, the cutoff for hsTnT at 48 h and mortality was 1640 ng/l. After adjustment for IMPACT score multivariate logistic and linear regression showed independent associations between hsTnT and mortality/DAOH with odds ratio of 8.10 [95%CI 2.99–21.89] and unstandardized regression coefficient of −1.54 [95%CI −2.02 to −1.06], respectively. Conclusion Postoperative hsTnT might be suitable as an early prognostic marker after HTX and is independently associated with 1-year mortality and poor DAOH.

show abstract

Section: Discussionsupporting

confidence: 57%

Postoperative high-sensitivity troponin T predicts 1-year mortality and days alive and out of hospital after orthotopic heart transplantation

et al. 2023

View full text Add to dashboard Cite

show abstract

“…(consensus: 100%) There is often a mismatch between the clinician's assessment of the patient's quality of life and the patient's own assessment. Health-related quality of life is usually assessed using patient questionnaires or instruments [27][28][29][30][31][32][33][34]. These questionnaires should be relevant and acceptable to both patients and the general population and should use simple language, understandable to the patient and be culturally relevant.…”

Section: Statementmentioning

confidence: 99%

European Society for Organ Transplantation (ESOT) Consensus Statement on Outcome Measures in Liver Transplantation According to Value-Based Health Care

Carbone,

Neuberger,

Rowe

et al. 2024

Transpl Int

View full text Add to dashboard Cite

Liver transplantation is a highly complex, life-saving, treatment for many patients with advanced liver disease. Liver transplantation requires multidisciplinary teams, system-wide adaptations and significant investment, as well as being an expensive treatment. Several metrics have been proposed to monitor processes and outcomes, however these lack patient focus and do not capture all aspects of the process. Most of the reported outcomes do not capture those outcomes that matter to the patients. Adopting the principles of Value-Based Health Care (VBHC), may provide an opportunity to develop those metrics that matter to patients. In this article, we present a Consensus Statement on Outcome Measures in Liver Transplantation following the principles of VBHC, developed by a dedicated panel of experts under the auspices of the European Society of Organ Transplantation (ESOT) Guidelines’ Taskforce. The overarching goal is to provide a framework to facilitate the development of outcome measures as an initial step to apply the VMC paradigm to liver transplantation.

show abstract

“…48 There are ongoing efforts to develop transplant-specific PROMs, including for solid organ transplant recipients. 48,49…”

Section: Types Of Promsmentioning

confidence: 99%

Novel Endpoints in Solid Organ Transplantation: Targeting Patient-reported Outcome Measures

Cazzolli

Howell

et al. 2023

Transplantation

View full text Add to dashboard Cite

Although solid organ transplantation improves survival and quality of life in many patients with organ failure, treatment complications and side effects can have debilitating consequences for patients. Patient-reported outcome measures (PROMs) capture how patients feel and function, including quality of life, symptoms, and side effects that are assessed directly by patients. Yet, they remain infrequently reported in trials in solid organ transplantation. Barriers to implementing PROMs in trials include uncertainty in selecting appropriate PROMs, concerns about resources limitations, patient burden, and limited evidence to support the psychometric robustness of measures for use in transplant recipients. In recent years, there have been increasing efforts to include patient-reported outcomes that are important to patients in trials to ensure that trials provide patient-centered information for decision-making. This article will provide an overview of PROMs, discuss PROs that are important to solid organ transplant recipients and those that are used in trials in solid organ transplantation, and outline approaches for selecting PROMs for clinical trials.

show abstract

Implementation of patient‐reported outcome measures in a heart transplant recipient registry: First step toward a patient‐centered approach

Cited by 7 publications

References 85 publications

Postoperative high-sensitivity troponin T predicts 1-year mortality and days alive and out of hospital after orthotopic heart transplantation

Postoperative high-sensitivity troponin T predicts 1-year mortality and days alive and out of hospital after orthotopic heart transplantation

European Society for Organ Transplantation (ESOT) Consensus Statement on Outcome Measures in Liver Transplantation According to Value-Based Health Care

Novel Endpoints in Solid Organ Transplantation: Targeting Patient-reported Outcome Measures

Contact Info

Product

Resources

About